The answer is complicated.

The agency is still reviewing submissions. Still clearing devices. Still conducting inspections. But many of the traditional mechanisms industry relies on to understand FDA’s thinking—guidance updates, public communication, interpretive clarity—have become noticeably less stable.

In this clip from a recent webinar discussion, we talk through what that looks like in practice:

• de novos with placeholder regulations,

• AI-assisted review tools like ELSA,

• delayed guidance modernization,

• QMSR implementation pressures,

• and the growing need for companies to interpret FDA behavior in real time rather than rely solely on published documentation.

There’s also a broader question underneath all of this: what happens when regulatory systems continue functioning operationally while becoming less transparent interpretively?

That’s where things start getting interesting.

It’s not.

In many cases, that’s where the real challenges begin.

FDA gives you permission to market your device. It does not give anyone a reason to buy it—or pay for it. And that’s where launches stall.

Regulatory and reimbursement are often treated as separate steps: first approval, then payment. But they answer very different questions. The FDA is focused on safety and efficacy. Payers are focused on outcomes and economic value. One does not guarantee the other.

By the time companies start thinking seriously about reimbursement, it’s often too late. Clinical endpoints are already set, studies are complete, and the evidence gaps are locked in. At that point, you’re not building strategy—you’re fixing it. And that’s always more expensive.

Investors have learned this the hard way. Clearance alone isn’t enough. They want to understand how the device will be reimbursed, whether providers will adopt it, and whether there’s a real economic case behind it. Because a cleared device that doesn’t get used isn’t a business.

The companies that succeed don’t treat regulatory, reimbursement, and commercialization as separate workstreams. They align them early, making deliberate decisions about clinical strategy, indications, and evidence with both approval and payment in mind.

FDA clearance isn’t the finish line. It’s where commercial reality begins.

In this clip, leanRAQA’s Renae Franz breaks down a simple but underused framework that separates fast-moving products from decade-long slogs:

“If the commercialization is done right, it’s usually one to two years.”

That only applies when the market already understands both the problem and the solution.

From there, timelines expand quickly:

• Known problem + unknown solution → 3–5 years

• Unknown problem + unknown solution → 10+ years, even for low-risk devices

The example is hard to ignore:
A nasogastric tube placement issue—impacting ~30% of cases—took over a decade to move from awareness to adoption, despite being clinically critical.

“This device… took till 2021 to really get market traction.”

The takeaway isn’t theoretical:
Most founders—and many investors—underestimate commercialization timelines because they assume adoption behaves like approval.

It doesn’t.

Catch the full presentation here: https://youtu.be/Y_QojHiu4dQ

They get into trouble because they drift.

In this Executive Briefing, we break down a pattern that shows up repeatedly in FDA warning letters:

• Teams treat websites and marketing as separate from labeling

• Claims evolve over time without being checked against original clearance

• “Technically true” statements create misleading impressions

• Small wording changes quietly alter intended use—and regulatory classification

Drawing directly from real enforcement examples, this session walks through how claims move from harmless to high-risk—and why leadership teams often don’t see it happening.

You can catch the full presentation here: https://youtu.be/TAzdwZ6n_LE

This clip examines the warning letter, Apple’s parallel 510(k) clearance, and the broader implications of “inherent use” in digital health.

The takeaway isn’t outrage. It’s evolution.

Watch the full video here: https://youtu.be/ERr9Yml-7HQ